Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 893

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 893
---
 $ | 762 | ​ | ​ | ​ | ​                  | $ | -62,839 | ​ | ​ | ​ | ​                                 | $ |   — | ​ | ​ | ​ | ​                         | $ | -62,058 | ​ | ​ |

The accompanying notes are an integral part of these financial statements. F-93

TABLE OF CONTENTS

Tvardi Therapeutics, Inc. Statements of Cash Flows
(Amounts in thousands)

| ​                                                                                            
 ​                                                                                            | ​ 
 ​ | ​ 
 ​ | For the Year Ended December 31, 
 2023                            |   |         |   | ​ | ​ | 2022 |   |         |   | ​ 
 ​ |
|:---------------------------------------------------------------------------------------------|:--|:--|:--------------------------------|:--|--------:|:--|:--|:--|:-----|:--|--------:|:--|:--|
| Cash flows from operating activities:                                                        | ​ | ​ | ​                               | ​ |       ​ | ​ | ​ | ​ | ​    | ​ |       ​ | ​ | ​ |
| Net loss                                                                                     | ​ | ​ | ​                               | $ | -17,347 | ​ | ​ | ​ | ​    | $ | -20,542 | ​ | ​ |
| Adjustments to reconcile net loss to net cash used in operating activities:                  | ​ | ​ | ​                               | ​ |       ​ | ​ | ​ | ​ | ​    | ​ |       ​ | ​ | ​ |
| Depreciation and amortization expense                                                        | ​ | ​ | ​                               | ​ |      95 | ​ | ​ | ​ | ​    | ​ |      85 | ​ | ​ |
| Stock-based compensation expense                                                             | ​ | ​ | ​                               | ​ |     314 | ​ | ​ | ​ | ​    | ​ |     246 | ​ | ​ |
| Non-cash lease expense                                                                       | ​ | ​ | ​                               | ​ |      51 | ​ | ​ | ​ | ​    | ​ |      34 | ​ | ​ |
| Accretion of discounts on short-term investments                                             | ​ | ​ | ​                               | ​ |    -194 | ​ | ​ | ​ | ​    | ​ |    -355 | ​ | ​ |
| Changes in operating assets and liabilities:                                                 | ​ | ​ | ​                               | ​ |       ​ | ​ | ​ | ​ |